Developmental neuroscience

Acorn Health Acquires Sandcastle Centers in Orlando, FL

Retrieved on: 
Monday, March 22, 2021
Children, General Health, Health, Consumer, Mind, Psychology, Articles, Psychiatric diagnosis, Developmental neuroscience, Developmental psychology, Autism, Behaviorism, Acorn Computers, Autism spectrum, Applied behavior analysis, Association of Community Organizations for Reform Now

Acorn Health, a national provider of Applied Behavior Analysis (ABA) therapy for children diagnosed with Autism Spectrum Disorder (ASD), is pleased to announce the acquisition of the assets of Sandcastle Centers (Sandcastle).

Key Points: 
  • Acorn Health, a national provider of Applied Behavior Analysis (ABA) therapy for children diagnosed with Autism Spectrum Disorder (ASD), is pleased to announce the acquisition of the assets of Sandcastle Centers (Sandcastle).
  • Sandcastle, formerly known as JKP Analysts, is now a wholly owned subsidiary of Acorn Health.
  • We are excited about the acquisition of Sandcastle Centers, said Vicki Kroviak, CEO of Acorn Health.
  • Acorn Health is a national provider of ABA therapy with locations in Michigan, Illinois, Virginia, Florida, Maryland, Pennsylvania, and Tennessee.

Chiasma Presents New Positive Data for MYCAPSSA from Phase 3 Trial MPOWERED™ for the Maintenance Treatment of Acromegaly at ENDO 2021

Retrieved on: 
Saturday, March 20, 2021
Branches of biology, Organ systems, Neuroendocrinology, Developmental neuroscience, Insulin-like growth factor 1, Somatostatin

The data from MPOWERED showed that MYCAPSSA improved clinical symptoms and other patient-reported outcomes compared to long-acting injectable somatostatin receptor ligands (iSRLs) in patients with acromegaly.

Key Points: 
  • The data from MPOWERED showed that MYCAPSSA improved clinical symptoms and other patient-reported outcomes compared to long-acting injectable somatostatin receptor ligands (iSRLs) in patients with acromegaly.
  • Based on these data, we remain focused on submitting a marketing authorization application for MYCAPSSA to the European Medicines Agency planned for mid-2021.
  • MYCAPSSA demonstrated stable IGF-1 levels during the RCT phase comparable to iSRLs, supporting efficacy of MYCAPSSA.
  • Overall, 80.4% of the randomized patients maintained or improved their symptoms score during the run-in phase compared to baseline.

NIH research delivers promising results for non-verbal children with autism using Video-Assisted Speech Therapy (VAST)

Retrieved on: 
Thursday, March 18, 2021
Autism, Branches of biology, Psychiatric diagnosis, Abnormal psychology, Psychiatry, Pervasive developmental disorders, Autism spectrum, Developmental neuroscience, Virtual reality, Draft:Healis Autism Centre, Autism therapies

The research project measured the impact of iTherapy's Video-Assisted Speech Therapy Software on functional language abilities in non- and minimally verbal children with autism spectrum disorder (ASD).

Key Points: 
  • The research project measured the impact of iTherapy's Video-Assisted Speech Therapy Software on functional language abilities in non- and minimally verbal children with autism spectrum disorder (ASD).
  • iTherapy, LLC Bay Area developers of immersive educational technology for those with communication challenges, such as autism today announced exciting results from a Phase I NIH-funded research project.
  • Results showed measurable positive changes in the areas of imitation, accuracy, joint attention, and social referencing, after just seven weeks.
  • All participating children completed a three-minute VAST session, twice a week either on a tablet or using a virtual-reality (VR) headset.

REC 0/0559: Also Known as MT-8 - A Low Molecular Weight Non-peptidic Human Nerve Growth Factor (NGF) Mimetic - Global Emerging Insight and Market Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 16, 2021
Health, Genetics, Branches of biology, Biology, Neurotrophic factors, Neurotrophic keratitis, Developmental neuroscience, Nerve growth factor, Keratitis

REC 0/0559 (also known as MT-8 or REC-0559) is a low molecular weight non-peptidic human nerve growth factor (NGF) mimetic currently under global development by Recordati.

Key Points: 
  • REC 0/0559 (also known as MT-8 or REC-0559) is a low molecular weight non-peptidic human nerve growth factor (NGF) mimetic currently under global development by Recordati.
  • "REC 0/0559 - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Persistent Epithelial Defect in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
  • FDA has granted Orphan Drug Designation to Recordati Rare Disease's investigational product REC 0559 for the treatment of neurotrophic keratitis.

Fraser Opens Autism Center of Excellence® in Maple Grove

Retrieved on: 
Thursday, March 11, 2021
Branches of biology, Psychiatric diagnosis, Psychiatry, Neuroscience, Autism, Autism spectrum, Developmental neuroscience, Developmental psychology

MAPLE GROVE, Minn., March 11, 2021 /PRNewswire/ --In Minnesota, 1 in 44 children is diagnosed with autism.

Key Points: 
  • MAPLE GROVE, Minn., March 11, 2021 /PRNewswire/ --In Minnesota, 1 in 44 children is diagnosed with autism.
  • To serve this growing need,Fraser Minnesota's largest and most experienced provider of autism services opened a new Autism Center of Excellencesatellite location in Maple Grove, MN, on March 8, to serve 24 children and their families.
  • The Autism Center of Excellence satellite location provides individualized, intensive autism services forautism spectrum disordersin children, ages 18 months to 7years.
  • "At Fraser, we don't believe in a one-size-fits-all approach," says Rachel Gardner, Director of Fraser Autism Center of Excellence.

Quality Autism Therapy, Now Accessible at Multiple Colorado Locations

Retrieved on: 
Friday, February 26, 2021
Psychology, Mind, Psychiatric diagnosis, Branches of biology, Autism, Developmental neuroscience, Developmental psychology, Behaviorism, Autism spectrum, Applied behavior analysis, Draft:Hopebridge Autism Therapy Centers, Autism therapies

The company recently completed its 20th year in business, and has over 55 centers across Texas, Oklahoma, and Colorado.

Key Points: 
  • The company recently completed its 20th year in business, and has over 55 centers across Texas, Oklahoma, and Colorado.
  • ABA therapy is a science-based discipline that helps manage behavioral conditions brought on by Autism Spectrum Disorder (ASD).
  • Behavioral Innovations is a trailblazer in delivering 1-to-1 personalized treatment plans, which ensures undivided attention to the kids when they enroll at one of their locations.
  • People can follow them on Facebook and Instagram to receive regular updates on ABA Therapy and autism resources.

The changing dynamics of the Argininosuccinic aciduria market, Complement 3 glomerulopathy market, Dup15q syndrome market, Fragile X syndrome market, and Neurofibromatosis Type-2 (NF2) market: Analysis by DelveInsight

Retrieved on: 
Wednesday, February 24, 2021
Branches of biology, Psychiatric diagnosis, Health, Clinical medicine, Learning disabilities, Genetics of autism, Dup15q, Developmental neuroscience, Fragile X syndrome, FXS, Autism spectrum, Autism

Children with 15q11-q13 duplications are at high risk for neurodevelopmental disabilities, particularly autism spectrum disorder (ASD) and intellectual disability (ID).

Key Points: 
  • Children with 15q11-q13 duplications are at high risk for neurodevelopmental disabilities, particularly autism spectrum disorder (ASD) and intellectual disability (ID).
  • The total Dup15q syndrome prevalent population in the 7MM in 2020 was reported to be 46,250 which shall surpass the figure of 47,500 in next 10 years.
  • Fragile X syndrome (FXS) or Martin-Bell syndrome is a form of intellectual disability (ID) following an X-linked inheritance pattern.
  • DelveInsight anticipates steep growth of the Fragile X syndrome with a CAGR of 32.6% in the study period 20182030.

The changing dynamics of the Argininosuccinic aciduria market, Complement 3 glomerulopathy market, Dup15q syndrome market, Fragile X syndrome market, and Neurofibromatosis Type-2 (NF2) market: Analysis by DelveInsight

Retrieved on: 
Wednesday, February 24, 2021
Branches of biology, Psychiatric diagnosis, Health, Clinical medicine, Learning disabilities, Genetics of autism, Dup15q, Developmental neuroscience, Fragile X syndrome, FXS, Autism spectrum, Autism

Children with 15q11-q13 duplications are at high risk for neurodevelopmental disabilities, particularly autism spectrum disorder (ASD) and intellectual disability (ID).

Key Points: 
  • Children with 15q11-q13 duplications are at high risk for neurodevelopmental disabilities, particularly autism spectrum disorder (ASD) and intellectual disability (ID).
  • The total Dup15q syndrome prevalent population in the 7MM in 2020 was reported to be 46,250 which shall surpass the figure of 47,500 in next 10 years.
  • Fragile X syndrome (FXS) or Martin-Bell syndrome is a form of intellectual disability (ID) following an X-linked inheritance pattern.
  • DelveInsight anticipates steep growth of the Fragile X syndrome with a CAGR of 32.6% in the study period 20182030.

Viridian Therapeutics to Present at Three Upcoming Investor Conferences

Retrieved on: 
Monday, February 22, 2021
Branches of biology, Biology, Developmental neuroscience, Insulin-like growth factor 1

Webcast information for these events will be accessible on the Events page under the Investors section of the Viridian Therapeutics website at www.viridiantherapeutics.com .

Key Points: 
  • Webcast information for these events will be accessible on the Events page under the Investors section of the Viridian Therapeutics website at www.viridiantherapeutics.com .
  • Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by todays therapies.
  • Viridians most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody in development for thyroid eye disease (TED).
  • These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.

FAST and SFARI to launch International Angelman Syndrome Research Council (INSYNC-AS)

Retrieved on: 
Friday, February 19, 2021
Branches of biology, Neurological disorders, Health, Clinical medicine, Learning disabilities, Psychiatric diagnosis, Simons Foundation Autism Research Initiative, Angelman syndrome, Developmental neuroscience, Neurodevelopmental disorder

DOWNERS GROVE, Ill., Feb. 19, 2021 (GLOBE NEWSWIRE) -- FAST (Foundation for Angelman Syndrome Therapeutics) and the Simons Foundation Autism Research Initiative (SFARI) today announced a collaboration to launch the International Angelman Syndrome Research Council (INSYNC-AS).

Key Points: 
  • DOWNERS GROVE, Ill., Feb. 19, 2021 (GLOBE NEWSWIRE) -- FAST (Foundation for Angelman Syndrome Therapeutics) and the Simons Foundation Autism Research Initiative (SFARI) today announced a collaboration to launch the International Angelman Syndrome Research Council (INSYNC-AS).
  • Using a robust integrated approach, the Council will evaluate and drive research initiatives in Angelman syndrome (AS) and other neurodevelopmental disorders (NDDs).
  • FAST (Foundation for Angelman Syndrome Therapeutics) is a Section 501(c)(3) nonprofit research organization singularly focused on funding research that holds the greatest promise of treating Angelman syndrome.
  • Since its launch in 2006, SFARI has supported over 550 investigators doing autism-related research in the U.S. and abroad.